Skip to main content
. 2024 Jan 6;16:17588359231220510. doi: 10.1177/17588359231220510

Figure 4.

Figure 4.

Panel A: Median PFS from date of start of ICI (N = 217). High CTLA-4 indicates ⩾ 75th percentile RNA expression; low/moderate CTLA-4 indicates < 75th percentile RNA expression. The median PFS in the high CTLA-4 (N = 41) expressed cohort was 7.7 months (4–21.8 months, 95% CI) versus 4.6 months (3.7–5.3, 95% CI) in the low/moderate CTLA-4 cohort (N = 176) (HR, 95% CI for high versus non-high CTLA-4 PFS was 0.6 [0.4–0.9, 95% CI; p = 0.008]). These results indicate that high versus non-high CTLA-4 was predictive for a longer PFS after immunotherapy. Panel B: Median OS from the date of start of ICI in patients treated with an ICI (N = 217). High CTLA-4 indicates ⩾ 75th percentile RNA expression; low/moderate CTLA-4 indicates < 75th percentile RNA expression. The median OS in the high CTLA-4 (N = 41) expressed cohort was 39.6 months (16.8–NE, 95% CI) versus the median OS in the low/moderate CTLA-4 (N = 176) expressed cohort at 14.5 months (11.4–18.5 months, 95% CI). HR (95% CI) = 0.5 (0.3–0.8; p = 0.002) for high versus non-high CTLA-4 OS. These results indicate high versus non-high CTLA-4 RNA expression was predictive for longer OS after ICI.

ICI, immune checkpoint inhibitors; PFS, progression-free survival.